Related LncRNAs
ID	lncRNA Name	Disease	Method	Sample	Expression pattern	Dysfunction type	Description	PMID	Source
EL0343	DLEU1	multiple myeloma	FISH	myeloma cases	N/A	locus	A cdr of approximately 350 kb was identified at 13q14 with the proximal border approximately 120 kb centromeric from d13s319, encompassing an area rich in expressed sequence tagged sites and containing dleu1, dleu2, and rfp2 genes.	12461754
EL0344	DLEU2	multiple myeloma	FISH	myeloma cases	N/A	locus	A cdr of approximately 350 kb was identified at 13q14 with the proximal border approximately 120 kb centromeric from d13s319, encompassing an area rich in expressed sequence tagged sites and containing dleu1, dleu2, and rfp2 genes.	12461754
EL0526	GAS5	multiple myeloma	qPCR etc.	blood (plasma)	down-regulated	expression	HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients.	24583225	LncRNADisease Lnc2Cancer
EL0578	HOTAIR	multiple myeloma	qPCR etc.	blood (plasma)	down-regulated	expression	HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients.	24583225	LncRNADisease Lnc2Cancer
EL0853	MALAT1	multiple myeloma	qPCR etc.	blood (plasma)	down-regulated	expression	HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients.	24583225	LncRNADisease Lnc2Cancer
EL0853	MALAT1	multiple myeloma	qPCR etc.	Bone marrow	up-regulated	N/A	MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients and healthy individuals. The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment.	25369863	LncRNADisease Lnc2Cancer
EL0853	MALAT1	multiple myeloma	qPCR, Luciferase reporter assay, ELISA, knockdown etc.	bone marrow	up-regulated	expression	The expression of MALAT1 was assessed by quantitative qPCR. Consistently higher expression level of MALAT1 was found in MSCs from all 25 patient samples relative to that from healthy donors. lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoter to increase expression of LTBP3 gene. The specificity and efficiency of activation were ensured by the formation of a stable complex between MALAT1 and the LTBP3 promoter, direct interaction of MALAT1 with Sp1 and recruitment of Sp1 to the promoter.	25187517	Lnc2Cancer
EL0861	MEG3	multiple myeloma	knockdown, overexpression, ChIP, RIP	bone marrow mesenchymal stromal cells (MSCs)	down-regulated	expression	Our data provided novel evidence for the biological and clinical significance of lncRNA MEG3 expression as a potential biomarker for identifying patients with MM and as a potential therapeutic target in MM.	25753650
EL1102	PVT1	multiple myeloma	qPCR, FISH etc.	cell lines (AMU-MM1, KMS-12-BM, KMS-18, KMS-20 etc.)	differential expression	N/A	PVT1 rearrangements were most common and found in 7 of 12 patients (58.3%) and 5 of 8 cell lines (62.5%) with 8q24 abnormalities. A combination of spectral karyotyping (SKY), FISH, and oligonucleotide array identified several partner loci of PVT1 rearrangements, such as 4p16, 4q13, 13q13, 14q32, and 16q23-24. The PVT1-NBEA chimera in which PVT1 exon 1 was fused to NBEA exon 2 and the PVT1-WWOX in which PVT1 exon 1 was fused to WWOX exon 9 were associated with the expression of abnormal NBEA and WWOX lacking their N-terminus, respectively. These findings suggest that PVT1 rearrangements may represent a novel molecular paradigm underlying the pathology of 8q24 rearrangement-positive multiple myeloma.	22869583	Lnc2Cancer
EL1351	TP73-AS1	multiple myeloma	methylation-specific PCR etc.	cell lines (KMS-12-PE, LP-1, NCI-H929, OPM-2, OCI-MY5)	differential expression	expression	Herein, by methylation-specific PCR, the putative KIAA0495 promoter was found unmethylated in all healthy controls (N = 14) but methylated in 50 % of myeloma cell lines (N = 10). KIAA0495 methylation was shown inversely correlated with KIAA0495 expression. However, KIAA0495 methylation was detected in none of both primary myeloma samples at diagnosis (N = 61) and at relapse/progression (N = 16). Collectively, despite frequently methylated in cell lines, KIAA0495 methylation appeared unimportant in the pathogenesis or progression of myeloma.	26410378	Lnc2Cancer
EL1399	TUG1	multiple myeloma	qPCR etc.	blood (plasma)	up-regulated	N/A	In our study, TUG1 levels were investigated in cell free plasma samples and higher expression was only observed in the MM group although correlation with disease state was observed both in the CLL and MM groups.	24583225	LncRNADisease Lnc2Cancer